Funding round
Ollin Biosciences Series A
Ollin Biosciences, a pharmaceutical products company in Austin, raised $100M in a Series A round announced on 17 Sep 2025, led by ARCH Venture Partners, Mubadala Capital and Monograph Capital. 3 firms took part. It is Ollin Biosciences' first venture round on record.
$100M
Amount raised
Not disclosed
Post-money valuation
3
Investors
3 leads
Valuation
What this round says about the price
Ollin Biosciences did not disclose a valuation in this round. It is Ollin Biosciences' first venture round on record, 2 years after it was founded in 2023. It is 23% of the $430M Ollin Biosciences has raised in the venture rounds on record. Ollin Biosciences raised again 9 months later: a Series B round of $330M in Jun 2026.
Ollin Biosciences' funding rounds
Ollin Biosciences has 2 venture rounds on record. This one is highlighted.
- Series A this round 17 Sep 2025, led by ARCH Venture Partners, Mubadala Capital and Monograph Capital $100M
- Series B 24 Jun 2026, led by TCG Crossover and ARCH Venture Partners $330M
Investors
Who put money in
ARCH Venture Partners, Mubadala Capital and Monograph Capital led the round.
Lead investors
- ARCH Venture Partners backs 99 venture-backed companies new investor
- Mubadala Capital backs 61 venture-backed companies new investor
- backs 10 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
97 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $19M, and this round was 5.3 times the median. The closest in time, other companies' Series A rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 30 Sep 2025 | $205M | not disclosed | Novo Holdings and SR One |
| Pharmaceutical Products | 5 Sep 2025 | $44M | not disclosed | not named |
| Pharmaceutical Products | 15 Sep 2025 | $14M | not disclosed | not named |
| Pharmaceutical Products | 16 Sep 2025 | $5.0M | not disclosed | not named |
| Pharmaceutical Products | 1 Sep 2025 | $5.0M | not disclosed | not named |
| Pharmaceutical Products | 1 Sep 2025 | $3.7M | not disclosed | not named |
| Pharmaceutical Products | 9 Oct 2025 | $165M | not disclosed | Sofinnova Partners and Novo Holdings |
| Phagos Pharmaceutical Products | 8 Oct 2025 | $29M | not disclosed | Capagro and Hoxton Ventures |
Sources
Where this comes from
Reported by 3 sources. The deal data marks this round as not yet confirmed by an official announcement. Unconfirmed
Questions
Frequently asked
How much did Ollin Biosciences raise in its Series A round?
Ollin Biosciences raised $100M in its Series A round, announced in Sep 2025.
Who led Ollin Biosciences' Series A round?
ARCH Venture Partners, Mubadala Capital and Monograph Capital led it.
What was Ollin Biosciences' valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Pharmaceutical Products?
97 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $19M, and this round was 5.3 times the median.
Did Ollin Biosciences raise again after this round?
Yes: a Series B round in Jun 2026 of $330M.